Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients

[1]  M. Okada,et al.  Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs , 2008, Oncogene.

[2]  G. Morgan,et al.  The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. , 2007, Cancer research.

[3]  Chi Ma,et al.  RAET1E2, a Soluble Isoform of the UL16-binding Protein RAET1E Produced by Tumor Cells, Inhibits NKG2D-mediated NK Cytotoxicity* , 2007, Journal of Biological Chemistry.

[4]  D. Fan,et al.  Establishment and Characterization of a High Metastatic Potential in the Peritoneum for Human Gastric Cancer by Orthotopic Tumor Cell Implantation , 2007, Digestive Diseases and Sciences.

[5]  M. Büchler,et al.  Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity , 2006 .

[6]  M. Colonna,et al.  The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. , 2006, Seminars in cancer biology.

[7]  A. Steinle,et al.  Proteolytic release of soluble UL16-binding protein 2 from tumor cells. , 2006, Cancer research.

[8]  U. Sen,et al.  Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1)* , 2006, Journal of Biological Chemistry.

[9]  M. Büchler,et al.  Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. , 2006, International journal of cancer.

[10]  Eric O Long,et al.  Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. , 2006, Blood.

[11]  L. Moretta,et al.  Cellular ligands of activating NK receptors. , 2005, Trends in immunology.

[12]  E. Lanino,et al.  Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). , 2005, Blood.

[13]  L. Moretta,et al.  PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. , 2005, Molecular immunology.

[14]  D. Louis,et al.  CD155/PVR plays a key role in cell motility during tumor cell invasion and migration , 2004, BMC Cancer.

[15]  R. Kiessling,et al.  Autocrine Secretion of Fas Ligand Shields Tumor Cells from Fas-Mediated Killing by Cytotoxic Lymphocytes , 2004, Cancer Research.

[16]  L. Rassenti,et al.  Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodies , 2004, Cancer.

[17]  S. Meri,et al.  Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form , 2004, European journal of immunology.

[18]  J. Marks,et al.  Treatment of Intracerebral Neoplasia and Neoplastic Meningitis with Regional Delivery of Oncolytic Recombinant Poliovirus , 2004, Clinical Cancer Research.

[19]  Lewis L Lanier,et al.  Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). , 2004, International immunology.

[20]  A. V. D. Stolpe,et al.  Intercellular adhesion molecule-1 , 2020, Journal of Molecular Medicine.

[21]  R. Förster,et al.  Characterization and identification of Tage4 as the murine orthologue of human poliovirus receptor/CD155. , 2003, Biochemical and biophysical research communications.

[22]  H. Blottière,et al.  Identification of secreted CD155 isoforms. , 2003, Biochemical and biophysical research communications.

[23]  L. Moretta,et al.  Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.

[24]  L. Young,et al.  Inhibition of Metalloproteinase Cleavage Enhances the Cytotoxicity of Fas Ligand1 , 2003, The Journal of Immunology.

[25]  M. Denis,et al.  Overexpression of the CD155 gene in human colorectal carcinoma , 2001, Gut.

[26]  W. Han,et al.  Preparation and characterization of mabs against different epitopes of CD226 (PTA1). , 2000, Hybridoma.

[27]  P. Altevogt,et al.  Role of Src Kinases in the ADAM-mediated Release of L1 Adhesion Molecule from Human Tumor Cells* , 2000, The Journal of Biological Chemistry.

[28]  C. Sautès-Fridman,et al.  Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. , 1999, Immunology letters.

[29]  W. Jia,et al.  Isolation of cDNAs encoding gibbon and monkey platelet and T cell activation antigen 1 (PTA1). , 1999, DNA sequence : the journal of DNA sequencing and mapping.

[30]  R. Aebersold,et al.  TLiSA1 (PTA1) Activation Antigen Implicated in T Cell Differentiation and Platelet Activation Is a Member of the Immunoglobulin Superfamily Exhibiting Distinctive Regulation of Expression* , 1997, The Journal of Biological Chemistry.

[31]  Y. DeClerck,et al.  Proteases and protease inhibitors in tumor progression. , 1997, Advances in experimental medicine and biology.

[32]  T. Mcclanahan,et al.  DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. , 1996, Immunity.

[33]  L. Lanier,et al.  Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II). , 1991, Journal of immunology.

[34]  G. Burns,et al.  Characterization of a novel membrane glycoprotein involved in platelet activation. , 1989, The Journal of biological chemistry.

[35]  J. Werkmeister,et al.  TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors , 1985, The Journal of experimental medicine.